Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 246

Results For "EMA"

3000 News Found

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Biotech | March 03, 2022

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal


Medix Biochemica announces expansion of its porfolio
Biotech | March 03, 2022

Medix Biochemica announces expansion of its porfolio

The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier


Merck KGaA reports higher profits on strong volumes across its businesses
News | March 03, 2022

Merck KGaA reports higher profits on strong volumes across its businesses

Company expects strong organic growth in sales, EBITDA in 2022


Mapmygenome launches Genomics Experience Centre in Bengaluru
Biotech | March 02, 2022

Mapmygenome launches Genomics Experience Centre in Bengaluru

At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors


Univar Solutions opens latest Solution Centre for its global ecosystem of innovation
News | March 02, 2022

Univar Solutions opens latest Solution Centre for its global ecosystem of innovation

State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond


Serina Fischer appointed GM India at Takeda Pharmaceuticals
People | March 02, 2022

Serina Fischer appointed GM India at Takeda Pharmaceuticals

Serina has over 17 years of experience in the biopharmaceutical industry


Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
Biotech | March 01, 2022

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review

If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.


USFDA approves CITI Biopharma’s Vonjo
Drug Approval | March 01, 2022

USFDA approves CITI Biopharma’s Vonjo

Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


China’s NMPA accepts supplemental NDA for Carteyva
Drug Approval | February 28, 2022

China’s NMPA accepts supplemental NDA for Carteyva

The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China